The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)--the Israeli arm of the INNOVATE study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples